Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinoma.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
09 08 2022
09 08 2022
Historique:
received:
06
04
2022
accepted:
21
07
2022
revised:
19
07
2022
entrez:
9
8
2022
pubmed:
10
8
2022
medline:
12
8
2022
Statut:
epublish
Résumé
Keap1 mutations regulate Nrf2 activity and lead to chemoresistance in cancers. Yet the underlying molecular mechanisms of chemoresistance are poorly explored. By focusing and genotyping head and neck squamous cell carcinoma (HNSCC) that had available pathologic and clinical data, we provide evidence that Keap1 displays frequent alterations (17%) in HNSCC. Functional loss of Keap1 results in significant activation of Nrf2 and promotes cancer cell growth, proliferation, and elevated cancer stem cell (CSCs) self-renewal efficiency and resistance to oxidative stress. Furthermore, decreased Keap1 activity in these cells increased nuclear accumulation of Nrf2 and activation of the Notch pathway, causing enhanced transcriptional alterations of antioxidants, xenobiotic metabolism enzymes, and resistance to chemotherapeutic treatment. Limiting the Nrf2 activity by either Keap1 complementation or by Nrf2 silencing increased the sensitivity to chemotherapy in Keap1-mutated cells and repressed the CSC self-renewal activity. Our findings suggest that Keap1 mutations define a distinct disease phenotype and the Keap1-Nrf2 pathway is one of the leading molecular mechanisms for clinical chemotherapeutic resistance. Targeting this pathway may provide a potential and attractive personalized treatment strategy for overcoming chemotherapeutic resistance conferred by Keap1 mutations.
Identifiants
pubmed: 35945195
doi: 10.1038/s41419-022-05126-8
pii: 10.1038/s41419-022-05126-8
pmc: PMC9363464
doi:
Substances chimiques
KEAP1 protein, human
0
Kelch-Like ECH-Associated Protein 1
0
NF-E2-Related Factor 2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
696Informations de copyright
© 2022. The Author(s).
Références
Ther Adv Med Oncol. 2020 Mar 13;12:1758835920911229
pubmed: 32206093
Cancer Lett. 2014 Nov 28;354(2):290-8
pubmed: 25173796
Nature. 2011 Jul 06;475(7354):106-9
pubmed: 21734707
Nucleic Acids Res. 2010 Sep;38(17):5718-34
pubmed: 20460467
Biochem Biophys Res Commun. 2017 Nov 4;493(1):833-839
pubmed: 28821430
Cell Stem Cell. 2014 Aug 7;15(2):199-214
pubmed: 24953182
Cell Death Dis. 2019 Nov 7;10(11):851
pubmed: 31699970
Oncotarget. 2014 Oct 15;5(19):8906-23
pubmed: 25275298
Nat Med. 2017 Nov;23(11):1362-1368
pubmed: 28967920
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Sci Signal. 2010 Jul 13;3(130):ra52
pubmed: 20628156
Nat Rev Drug Discov. 2013 Dec;12(12):931-47
pubmed: 24287781
Med Res Rev. 2012 Jul;32(4):687-726
pubmed: 22549716
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Arch Otolaryngol Head Neck Surg. 1987 Jul;113(7):762-4
pubmed: 3580159
N Engl J Med. 2007 Oct 25;357(17):1695-704
pubmed: 17960012
Precis Clin Med. 2019 Sep;2(3):152-165
pubmed: 31598386
J Assoc Res Otolaryngol. 2007 Sep;8(3):338-55
pubmed: 17516123
Gastroenterology. 2008 Oct;135(4):1358-1368, 1368.e1-4
pubmed: 18692501
Cancer Res. 2008 Mar 1;68(5):1303-9
pubmed: 18316592
Int J Biochem Cell Biol. 2005 Dec;37(12):2478-503
pubmed: 16103002
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Res. 2002 Sep 15;62(18):5196-203
pubmed: 12234984
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Chem Biol Interact. 2006 Mar 10;160(1):1-40
pubmed: 16430879
J Biol Chem. 2013 Mar 15;288(11):7803-7814
pubmed: 23349464
PLoS Med. 2006 Oct;3(10):e420
pubmed: 17020408
Cancer Discov. 2020 Dec;10(12):1826-1841
pubmed: 33071215
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Cell Death Dis. 2020 Aug 20;11(8):663
pubmed: 32814771
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562682
Nat Commun. 2018 Jul 9;9(1):2372
pubmed: 29985391
Cancer Res. 2012 Nov 1;72(21):5537-46
pubmed: 22964583
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
J Biol Chem. 1999 Mar 5;274(10):6443-52
pubmed: 10037736
Curr Treat Options Oncol. 2012 Mar;13(1):35-46
pubmed: 22252884
Elife. 2017 Feb 01;6:
pubmed: 28145866
Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):762-6
pubmed: 16847186
Free Radic Biol Med. 2015 Nov;88(Pt B):101-107
pubmed: 26057936
J Hematol Oncol. 2016 Sep 06;9(1):83
pubmed: 27601007
Cancer Res. 2019 Jul 1;79(13):3251-3267
pubmed: 31040157
Oxid Med Cell Longev. 2016;2016:7316492
pubmed: 27847554
Biochim Biophys Acta. 2014 Dec;1846(2):494-509
pubmed: 25270772
J Natl Cancer Inst. 2019 May 1;111(5):490-497
pubmed: 30239887
Cancers (Basel). 2018 Oct 10;10(10):
pubmed: 30308958
Clin Cancer Res. 2009 May 15;15(10):3423-32
pubmed: 19417020
Cancer Discov. 2017 Jan;7(1):86-101
pubmed: 27663899
Head Neck. 2015 May;37(5):727-34
pubmed: 24596130
Mayo Clin Proc. 2016 Mar;91(3):386-96
pubmed: 26944243
Mol Carcinog. 2015 Nov;54(11):1494-502
pubmed: 25154499
Biomolecules. 2020 Sep 25;10(10):
pubmed: 32992842
Front Oncol. 2017 May 04;7:85
pubmed: 28523248
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821